Bell Investment Advisors’s Vaxcyte PCVX Stock Holding History

Bell Investment Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.46K	Buy	94 +10	+12%	+$543	﹤0.01%	942
2026 Q1	$4.88K	Buy	84 +9	+12%	+$489	﹤0.01%	970
2025 Q4	$3.46K	Sell	75 -8	-10%	-$358	﹤0.01%	1139
2025 Q3	$2.99K	Buy	83 +48	+137%	+$1.59K	﹤0.01%	1165
2025 Q2	$1.14K	Sell	35 -44	-56%	-$1.44K	﹤0.01%	1552
2025 Q1	$2.98K	Hold	79	–	–	﹤0.01%	1143
2024 Q4	$6.47K	Hold	79	–	–	﹤0.01%	797
2024 Q3	$9.03K	Hold	79	–	–	﹤0.01%	662
2024 Q2	$5.97K	Buy	79 +10	+14%	+$681	﹤0.01%	838
2024 Q1	$4.71K	Buy	69 +8	+13%	+$554	﹤0.01%	954
2023 Q4	$3.83K	Buy	61 +2	+3%	+$104	﹤0.01%	1016
2023 Q3	$3.01K	Hold	59	–	–	﹤0.01%	1079
2023 Q2	$2.95K	Buy	59 +46	+354%	+$2.18K	﹤0.01%	1101
2023 Q1	$488	Buy	+13	New	+$551	﹤0.01%	1841
2022 Q4	–	Sell	-28	Closed	-$1K	–	2003
2022 Q3	$1K	Buy	+28	New	+$710	﹤0.01%	1519

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Bell Investment Advisors's PCVX Position: Q2 2026 in Review

Bell Investment Advisors increased its Vaxcyte (PCVX) stake by 12% in Q2 2026, buying an estimated $543 and bringing the position to 94 shares worth $5.46K. The position accounts for ﹤0.01% of the portfolio, ranked #942.

Bell Investment Advisors first reported a position in PCVX in Q3 2022 and has held it in 15 quarters since. The position peaked at $9.03K in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Bell Investment Advisors held 94 shares of Vaxcyte worth $5.46K as of Q2 2026.
Bell Investment Advisors bought 10 Vaxcyte shares in Q2 2026, an estimated $543.
Vaxcyte made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #942 holding.
Bell Investment Advisors first reported a position in Vaxcyte in Q3 2022 and has held it in 15 quarters since.
Bell Investment Advisors's Vaxcyte position peaked at $9.03K in Q3 2024.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.